Corbus Pharmaceuticals updates corporate presentation, highlights CRB-701 OPSCC progress and CRB-913 obesity data
Meno di 1 minuto di lettura
Corbus Pharmaceuticals updated its corporate presentation highlighting CRB-701 registrational progress in OPSCC and positive Phase 1b CRB-913 obesity results.
Key Highlights:
- Filed Form 8-K furnishing updated management presentation (Exhibit 99.1) describing business and clinical progress.
- CRB-701: TEMPO-1 registrational 2L OPSCC study underway (first patient dosed Sept 2026); interim ORR readout expected Q1 2027.
- ASCO data: CRB-701 3.6 mg/kg showed 42.9% cORR in OPSCC with 6.3‑month DoR and manageable safety profile, supporting 3.6 mg/kg for registrational studies.
- CRB-913: Phase 1b CANYON-1 showed ~5% placebo-adjusted weight loss at 12 weeks (60 mg), favorable GI and psychiatric tolerability; Phase 2 monotherapy planned 1H 2027.
- Balance sheet snapshot: approximately $118M cash, cash equivalents & investments as of June 30, 2026; ~18.7M common shares outstanding (~22.4M fully diluted).
Original SEC Filing: Corbus Pharmaceuticals Holdings, Inc. [ CRBP ] - 8-K - Oct. 15, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.